Johnson & Johnson (J&J) recently shared that its medical technology businesses—including Cerenovus and Biosense Webster, as well as Abiomed, DePuy Synthes, and Ethicon—will now go by the name ‘Johnson & Johnson MedTech’.
This move “underscores J&J’s leadership in medical technology with a focus on cardiovascular, orthopaedic, surgery and vision solutions”, according to a company press release, and is the next step of J&J’s updated brand and visual identity—which was originally announced in September 2023.
Moving forward, Cerenovus will be referred to as ‘Johnson & Johnson MedTech Neurovascular’, while Biosense Webster’s brand name has been updated to ‘Johnson & Johnson MedTech Electrophysiology’.
However, the announcement has no impact on the medical technology products and solutions currently offered to customers, the release adds.
“At Johnson & Johnson, we are addressing some of the largest unmet needs in healthcare through innovative medicine and medical technology,” said Tim Schmid, executive vice president and worldwide chairman of Johnson & Johnson MedTech. “By bringing our medtech businesses together under the J&J name, the scale of our impact in healthcare will be even more apparent, unlocking new opportunities for us to strengthen our competitiveness.
“While Ethicon, DePuy Synthes, Biosense Webster, Abiomed and Cerenovus will now go by Johnson & Johnson MedTech, we will continue to honour the legacies of these brands by maintaining the products, services and approach to collaboration that made them some of the most trusted names in healthcare.”
Partners, customers and consumers will begin to see the change “come to life” on social media channels and marketing materials over the coming weeks, J&J’s recent release notes, before also reiterating that its updated brand and visual identity will have no impact on the Johnson & Johnson MedTech portfolio.
